Aditxt Inc

Aditxt, Inc. engages in the development of biotechnologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring. It has a worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Richmond, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aditxt, Inc. is a biotech innovation company, which engages in the development and commercialization of technologies focusing on monitoring and modulating the immune system. Its innovation portfolio includes Adimune and AditxtScore. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Richmond, VA.

CEDARHURST, N.Y.--(BUSINESS WIRE)--Kuznicki Law PLLC is investigating the proposed sale of AiPharma Group Ltd. to Aditxt, Inc. (“the Company”) (NasdaqCM: ADTX). Under the terms of the proposed transaction, Aditxt will first acquire 9.5% of the issued and outstanding equity interests in AiPharma in exchange for the issuance of approximately 4.8 million shares of common stock of Aditxt and a cash payment of $250,000. Aditxt would then acquire the remaining 90.5% of the issued and outstanding equi

ADITXT INVESTOR ALERT - Kuznicki Law PLLC Investigates Aditxt, Inc. - ADTX

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt”, or the “Company”) (Nasdaq: ADTX), a biotech innovation company developing technologies focused on mapping and reprogramming the immune system, today is announcing a multiyear partnership with GRS, an affiliate of marketing powerhouse Guthy-Renker, LLC (“Guthy-Renker”). This partnership will focus on building awareness and visibility among consumers and healthcare providers for the AditxtScore™ Immune Monitoring Platform. Aditxt plans to wo

Aditxt, Inc. Partners with Guthy-Renker Affiliate GRS to Launch Consumer Awareness Campaign for AditxtScore™ to Accelerate Adoption and Revenue Growth

ADMA Biologics

Clovis Oncology

Can these penny stocks continue to climb after a bearish trading day? The post Best Penny Stocks to Watch After the Stock Market Takes a Bear Turn appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Watch After the Stock Market Takes a Bear Turn

CNS Pharmaceuticals

TD Holdings Inc

NextPlay Technologies

Penny stocks under $1 to watch in April 2022 The post Best Penny Stocks For April 2022? 4 Under $1 To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks For April 2022? 4 Under $1 To Watch Now

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company developing technologies focused on mapping and reprogramming the immune system, announced today that Company CEO & Co-Founder, Amro Albanna, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT. https://m-vest.com/events/2022-virtual-growth-conference/p/adtx Sign up here to access the pr

Aditxt to Participate in the 2022 Virtual Growth Conference

ADITXT INVESTOR ALERT - Kuznicki Law PLLC Investigates Adequacy of Price and Process in Proposed Sale of Aditxt, Inc. - ADTX

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of AiPharma Group Ltd. to Aditxt, Inc. (“the Company”) (NasdaqCM: ADTX). Under the terms of the proposed transaction, Aditxt will first acquire 9.5% of the issued and outstanding equity interests in AiPharma in exchange for the issuance of approximately 4.8 million shares of common stock of Aditxt and a cash paym

ADITXT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Aditxt, Inc. - ADTX

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt,” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to advance humanity's transition to the “Age of Immunity,” has submitted two EUA applications for AditxtScore™ for COVID-19. This lab-developed blood test provides a more comprehensive profile of the body's immune response to COVID-19. AditxtScore™ for COVID-19 not only indicates levels of protective immunity against the virus, but also seeks to map out the diffe

Aditxt Submits Two Requests for Emergency Use Authorization to FDA for AditxtScore™ for COVID-19 Tests Which Measure the Quantity and Quality of Antibodies Against COVID-19 and its Variants Including Omicron

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX) announced today it is participating in Edison Group's Open House Event, scheduled to take place virtually this month. The three-day event, in association with the London Stock Exchange, global law firm Taylor Wessing, and OpenExchange, will take place between January 25th-27th, focusing on 33 companies. Day one will feature businesses within pharmaceuticals & drug discovery, day two focuses on AI & t

Aditxt, Inc. to Participate in Edison Group's Global Healthcare “Open House” Virtual Conference From January 25th-27th, 2022

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it will host an online business update townhall meeting with Amro Albanna, Co-Founder & CEO on Tuesday, January 18th from 2:00 to 3:00 pm ET. The upcoming meeting will include, but is not limited to, commentary on the following topics: A business update and upcoming milestones A summary and discussion

Aditxt Provides Online Business Update Townhall Meeting with Amro Albanna, Co-Founder & CEO

NEW YORK, Dec. 29, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), in connection with the proposed merger of the Company with AiPharma Global Holdings LLC ("AiPharma").  Under the terms of the share exchange agreement, the Company will first acquire 9.5% of the issued and outstanding equity interests in AiPharma in exchange for the issuance of approximately 4.8 million shares of common stock of Aditxt and a cash payment of $250,000.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Aditxt, Inc.

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it had signed an amendment to its February 3, 2020, Exclusive License Agreement with Stanford University, extending Aditxt's exclusive right to license the technology deployed in AditxtScore™ and securing worldwide exclusivity in all fields of use of the licensed technology (the “Technology”). The Technol

Aditxt Signs Amendment to Extend Worldwide Licensing Agreement, Granting Exclusivity in all Fields of Use

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Aditxt Inc. (NASDAQ: ADTX) and AiPharma Global Holdings LLC is fair to Aditxt shareholders. Halper Sadeh encourages Aditxt shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Aditxt and its board violated t

Aditxt (ADTX) Stock Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Aditxt Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ADTX

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt Inc. (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, has signed a share exchange agreement to acquire AiPharma Global Holdings LLC, a wholly-owned subsidiary of AiPharma Group Ltd. (“AiPharma”). The share exchange agreement contemplates that the transaction would involve two steps. First, an initial closing is expected to occur upon the satisfaction of certain conditions no later than January 31, 2022

Aditxt Signs Share Exchange Agreement to Acquire AiPharma

Camber Energy

Pasithea Therapeutics Corp

Can these three penny stocks continue to make gains next month? The post Top Penny Stocks to Watch During Today's Bull Run appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Watch During Today's Bull Run

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it had signed a non-binding letter of intent (“LOI”) to acquire a company focused on developing Point-of-Care diagnostics for early detection of diseases including cancers and SARS-CoV-2 (COVID-19) through a range of non-invasive and affordable point of care and at-home/in-office test kits. Key strategic

Aditxt, Inc. Signs Non-Binding Letter of Intent to Acquire Point-of-Care Diagnostic Technology Development Company

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt”, or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the closing of its previously announced underwritten public offering of 16,575,000 units, consisting of shares of its common stock and warrants to purchase up to 16,575,000 shares of its common stock at a public offering price of $1.05 per unit, for aggregate gross proceeds of $17,403,750, prior to deduc

Aditxt Announces Closing of $17.4 Million Firm Commitment Public Offering of Common Stock and Warrants

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today that it has entered into an amendment to its previously announced transaction agreement with AiPharma Global extending the outside date by which the parties have to execute a definitive agreement from November 30, 2021 to December 16, 2021, and to remove the $4 million termination fee from the transaction

Aditxt Extends the Timeline to Sign the Definitive Agreement to Acquire AiPharma Global to December 16, 2021

Aditxt Inc (NASDAQ: ADTX) has priced an underwritten public offering of 16.575 million units, consisting of common shares and warrants to purchase up to 16.575 million shares at $1.05 per unit for gross proceeds of $17.4 million. The warrants permit the holder to purchase one share at an exercise price of $1.15 per share and expire five years after the date of issuance.

Aditxt Stock Plunges After Capital Raise Of $17M Via Equity

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt”, or the “Company”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the pricing of an underwritten public offering of 16,575,000 units, consisting of shares of its common stock (or pre-funded warrants to purchase common stock) and warrants to purchase up to 16,575,000 shares of its common stock at a public offering price of $1.05 per unit, for aggregate gross proceeds of

Aditxt Announces Pricing of $17.4 Million Firm Commitment Public Offering of Common Stock and Warrants Led by Leading Healthcare Investor

The stock price of Aditxt, Inc. (Nasdaq: ADTX) fell by over 18% pre-market today. This is why it happened.

Aditxt (ADTX) Stock: Why The Price Substantially Fell Today

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today the launch of an underwritten public offering. Dawson James Securities, Inc. is acting as sole book-running manager for the offering. The proposed offering of the common stock and warrants described above is being made pursuant to an effective “shelf” registration statement on Form S-3 (File No. 333-257645), that was prev

Aditxt Announces Proposed Public Offering of Common Stock and Warrants

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (Nasdaq: ADTX), a biotech innovation company that improves the health of the immune system, announced today that the Johnson County Sherriff's Office, the largest law enforcement agency in the State of Kansas with over 700 employees, will become the first agency in the Nation to deploy AditxtScore™ for assessing the immune status for COVID-19 in its employees. AditxtScore™ is an immune monitoring platform which provides a

The Largest Law Enforcement Agency in the State of Kansas, Johnson County Sherriff's Office, to Become First in the Nation to Deploy AditxtScore™ for Immune Scoring for its Employees and First Responders

Aditxt Inc (NASDAQ: ADTX) has announced data from Phase 3 PRESECO trial evaluating oral Avigan/Reeqonus (favipiravir) as a potential at-home therapy for mild-to-moderate COVID-19, run by Appili Therapeutics Inc. The trial did not achieve statistical significance on the primary endpoint of time to sustained clinical recovery. Additional analyses of the trial data are ongoing.

Aditxt Acquisition-Partner's At-Home COVID-19 Drug Fails In Late-Stage Trial

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), has announced a webinar at 2pm ET this afternoon to discuss its earlier announcement today. All investors are invited to attend, whether professional or individual. On today's webinar, CEO Amro Albanna will be sharing full information with all existing and potential investors. If you have questions, please submit them via email: aditxt@edisongroup.com. To join the webinar, click here at 2pm. Or paste the link directly into

News for Aditxt Inc Stock (ADTX)